₹309.20
−2.92%NSE close, 16 Nov 2026
+69.01%
Marksans Pharma is a small cap company in the Healthcare sector, listed on NSE under the symbol MARKSANS. At ₹309.20 a share, the market values the whole company at ₹14,016 crore.
In FY26, it reported sales of ₹2,951 crore and a net profit of ₹418 crore, an operating margin of 20.4%. Over the last three years, sales grew 16.8% a year and net profit grew 16.1% a year.
The market values the company at 25.0 times its profit over the last twelve months and 4.21 times its book value; its return on equity is 16.8% and it has almost no borrowings.
Promoters hold 43.87% of the shares. Foreign institutions hold 19.06%, and domestic institutions, mutual funds among them, 5.54%.
Over the past year the share price has risen 67.5%, and it is 11.9% below its 52-week high.
Companies of a similar size in the same sector include Poly Medicure, Natco Pharma, Indegene and Vijaya Diagnostic Centre.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Marksans Pharma | ₹309.20 | ₹14,016 cr | 25.0 | 16.8% | +30.50% | +67.52% |
| Poly Medicure | ₹1,684.30 | ₹17,072 cr | 53.6 | 9.8% | +30.80% | −11.21% |
| Natco Pharma | ₹828.65 | ₹16,255 cr | 19.6 | 8.5% | −29.00% | +3.52% |
| Indegene | ₹662.40 | ₹15,962 cr | 38.8 | 12.2% | +39.60% | +24.95% |
| Vijaya Diagnostic Centre | ₹1,487.50 | ₹15,321 cr | 75.2 | 19.3% |
Transcript
Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results
The Nomination and Remuneration Committee of the Company has Allotted Equity Shares under Marksans Employees Stock Option Scheme 2024
Press release dated 4 November 2026 regarding unaudited financial results for the quarter and half year ended 30 September 2026
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 586 | 560 | 591 | 642 | 682 | 70.9 | 620 | 720 | 754 | 856 | 841 | 940 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 453 | 450 | 462 | 506 | 543 | 58.3 | 520 | 576 | 594 | 661 | 628 | 726 |
| Operating profit | 133 | 110 | 128 | 136 | 139 | 12.6 | 100 | 144 | 161 | 195 | 213 | 214 |
| Operating margin | 22.7% | 19.6% | 21.7% | 21.1% | 20.4% | 17.8% | 16.1% | 20.1% | 21.3% | 22.8% | 25.3% | 22.8% |
| Other income | 4.8 | 16.5 | 15.0 | 11.1 | 27.9 | 1.7 | 5.6 | 21.6 | 20.1 | 35.2 | 25.4 | 18.2 |
| Interest | 3.2 | 4.8 | 2.9 | 2.6 | 2.7 | 0.3 | 6.1 | 5.8 | 5.9 | 6.3 | 7.0 | 6.8 |
| Depreciation | 22.0 | 21.1 | 20.4 | 19.5 | 20.7 | 2.3 | 23.1 | 26.9 | 24.3 | 24.3 | 24.9 | 32.1 |
| Profit before tax | 113 | 100 | 120 | 125 | 143 | 11.6 | 76.6 | 133 | 151 | 200 | 207 | 194 |
| Tax | 29.7 | 22.6 | 31.0 | 26.8 | 38.2 | 2.5 | 18.4 | 34.2 | 36.9 | 51.0 | 47.2 | 50.0 |
| Net profit | 83.2 | 72.7 | 88.8 | 96.7 | 105 | 9.1 | 58.3 | 98.3 | 113 | 148 | 157 | 141 |
| EPS (₹) | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 | 3.47 | 3.12 |
₹ crore, financial years to March.
| Line | FY18 S | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 295 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 262 | 2,951 |
| Expenses | 258 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 209 | 2,350 |
| Operating profit | 36.5 | 132 | 192 | 340 | 259 | 339 | 459 | 52.9 | 601 |
| Operating margin | 12.4% | 13.2% | 17.0% | 24.7% | 17.4% | 18.3% | 21.1% | 20.2% | 20.4% |
| Other income | 0.1 | 4.6 | 0.3 | 6.7 | 41.9 | 59.3 | 50.4 | 7.0 | 82.5 |
| Interest | 7.7 | 9.7 | 8.8 | 8.0 | 8.5 | 9.1 | 11.2 | 1.2 | 24.1 |
| Depreciation | 12.3 | 22.8 | 26.7 | 36.2 | 44.8 | 51.9 | 74.3 | 8.3 | 98.6 |
| Profit before tax | 16.7 | 104 | 157 | 302 | 248 | 338 | 424 | 50.4 | 561 |
| Tax | 4.2 | 23.9 | 36.4 | 63.6 | 60.7 | 72.3 | 109 | 12.1 | 140 |
| Net profit | 12.4 | 76.1 | 121 | 239 | 187 | 267 | 308 | 38.3 | 418 |
| EPS (₹) | 0.30 | 1.87 | 2.86 | 5.76 | 4.51 | 6.51 | 6.93 | 8.40 | 9.22 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 99.3 | 20.7 | 458 | 322 |
| From investing | −41.7 | −4.9 | −248 | −144 |
| From financing | 79.5 | −6.5 | −70.9 | −69.6 |
| Spent on fixed assets | −46.3 | −17.3 | −131 | −46.1 |
| Free cash flow | 52.9 | 3.4 | 328 | 275 |
Margins, returns, debt, tax and cash.
| Line | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|
| Net margin | 4.2% | 7.6% | 10.6% | 17.3% | 12.5% | 14.4% | 14.1% | 14.6% | 14.2% |
| Operating margin | 12.4% | 13.2% | 17.0% | 24.7% | 17.4% | 18.3% | 21.1% | 20.2% | 20.4% |
| Return on equity | – | – | – | – | – | 15.3% | 14.9% | 15.5% | 13.8% |
| Return on capital employed | – | – | – | – | – | 19.4% | 20.8% | 20.7% | 19.2% |
| Return on assets | – | – | – | – | – | 12.2% | 11.5% | 11.8% | 10.8% |
| Debt to equity | – | – | – | – | – | 0.02 | 0.01 | 0.01 | 0.01 |
| Interest coverage | 3.20 | 11.80 | 19.00 | 38.80 | 30.30 | 38.00 | 38.80 | 44.10 | 24.20 |
| Debt to assets | – | – | – | – | – | 0.02 | 0.01 | 0.01 | 0.01 |
| Current ratio | – | – | – | – | – | 4.91 | 4.78 | 4.62 | 5.17 |
| Quick ratio | – | – | – | – | – | 3.49 | 3.19 | 2.85 | 3.32 |
| Cash ratio | – | – | – | – | – | 1.12 | 1.03 | 1.04 | 1.20 |
| Asset turnover | – | – | – | – | – | 0.85 | 0.81 | 0.81 | 0.76 |
| Fixed asset turnover | – | – | – | – | – | 4.88 | 3.22 | 4.53 | 4.72 |
| Inventory turnover | – | – | – | – | – | – | 1.70 | 1.40 | 1.30 |
| Receivables turnover | – | – | – | – | – | 4.40 | 4.80 | 4.90 | 4.60 |
| Gross margin | – | – | – | – | – | – | 52.3% | 56.4% | 56.7% |
| Cash from operations to profit | – | – | – | – | 53.0% | – | – | 54.0% | 110.0% |
| Effective tax rate | 25.4% | 22.9% | 23.2% | 21.1% | 24.5% | 21.4% | 25.6% | 24.1% | 25.1% |
| +26.70% |
| +46.11% |
| Jubilant Pharmova | ₹960.25 | ₹15,295 cr | 58.2 | 3.7% | +20.50% | −17.28% |
|---|
| Rainbow Childrens Medicare | ₹1,276.80 | ₹12,968 cr | 44.4 | 17.0% | +23.20% | −6.37% |
|---|
| Concord Biotech | ₹581.00 | ₹12,156 cr | 43.0 | 13.6% | +25.10% | −17.67% |
|---|
| Metropolis Healthcare | ₹574.15 | ₹11,907 cr | 53.1 | 13.7% | +15.80% | +14.50% |
|---|
Unaudited financial results for the quarter and half year ended September 30, 2026.
Schedule for Q2FY27 Earnings Conference Call
Opening of Special Window for Re-lodgment of Transfer Requests of Physical Shares
Schedule of Investors Meet
A copy Srutinizers report along with voting result of Annual General Meeting held on August 27, 2026.
Proceedings of 34th Annual General Meeting held on August 27, 2026
Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ESG score by Crisil ESG Ratings & Analytics Ltd
Press Release dated 12 August 2026 on the unaudited financial results of the Company for the quarter ended 30 June 2026
The unaudited financial results for the quarter ended Jun 30, 2026.